Stocksigma LogoStocksigma Logo

Glenmark Pharma Launches Authorized Generic of INLYTA Tablets in the US

Glenmark Pharmaceuticals Inc., USA launched Axitinib Tablets (1 mg and 5 mg), an Authorized Generic version of Pfizer's INLYTA tablets, in the US market on

Glenmark Pharma Launches Authorized Generic of INLYTA Tablets in the US

Glenmark Pharmaceuticals Ltd 路 Press Release 路 16 Nov 2026, 2:10 pm

Glenmark Pharma Launches Authorized Generic of INLYTA Tablets in the US Glenmark Pharmaceuticals Inc., USA launched Axitinib Tablets (1 mg and 5 mg), an Authorized Generic version of Pfizer's INLYTA tablets, in the US market on 16th Nov'26. According to IQVIA sales data for the 12-month period ending Sep'26, INLYTA achieved annual US sales of approximately $538.4 million. The launch strengthens Glenmark's North American oncology and generic portfolio, targeting a substantial market opportunity.

Original exchange filing (PDF)

More announcements from Glenmark Pharmaceuticals Ltd

All Glenmark Pharmaceuticals Ltd announcements